Slate Medicines raises $130m in funds to progress anti-PACAP treatments

SLTE-1009 is a monoclonal antibody developed to target PACAP to prevent migraines and other headache disorders. Credit: Komsan Loonprom / Shutterstock.com.



  • Slate Medicines PACAP